Description
OSI-7904L is an investigational drug, meaning it is still being studied in clinical trials. It is not yet approved for use in treating colorectal cancer or any other condition. This drug was studied in a Phase 1 clinical trial for patients with advanced colorectal cancer that had not responded to standard treatments (refractory or recurrent). The trial combined OSI-7904L with oxaliplatin, a chemotherapy drug commonly used for colorectal cancer. The main goals of the trial were to find the highest safe dose of the combination, understand its side effects, and see if it had any activity against the cancer. The trial was a dose-escalation study, meaning researchers started with low doses and gradually increased them to find the maximum tolerated dose (MTD). The trial was completed, but the results regarding efficacy and long-term safety are not widely available or established.
Mechanism of Action
OSI-7904L is being investigated as a potential treatment for cancer. The specific way it works (its molecular target or mechanism of action) is not fully detailed in the available trial information. It was studied in combination with oxaliplatin, a chemotherapy drug that damages DNA in cancer cells to stop them from growing and dividing. The trial aimed to evaluate the safety and tolerability of combining OSI-7904L with oxaliplatin.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.